Of note, in addition to pharmacological treatment with riluzole [18], edaravone [19], and sodium phenylbutyrate/taurursodiol [20], the antisense oligonucleotide (ASO) tofersen, which reduces the synthesis of SOD1 protein by RNase H-dependent degradation of SOD1 messenger RNA [21], has been approved by the U.S. Food and Drug Administration (FDA) for patients with SOD1-ALS in April 2023. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.